Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients

被引:52
作者
Racek, Jaroslav
Kralova, Hana
Trefil, Ladislav
Rajdl, Daniel
Eiselt, Jaromir
机构
[1] Charles Univ Hosp Pilsen, Dept Clin Biochem & Haematol, Inst Clin Biochem & Haematol, CZ-30640 Plzen, Czech Republic
[2] Charles Univ Hosp Pilsen, Dept Internal Med 1, Plzen, Czech Republic
来源
NEPHRON CLINICAL PRACTICE | 2006年 / 103卷 / 04期
关键词
brain natriuretic peptide; N-terminal proBNP; haemodialysis; heart failure;
D O I
10.1159/000092914
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Brain natriuretic peptide (BNP) and N-terminal proBNP (NT- proBNP) are released into circulation as a result of congestive heart failure (HF). As HF and water overload are frequent complications in haemodialysis (HD) patients, we decided to study the levels of BNP and NT-proBNP and their changes during HD. Methods: BNP and NT-proBNP levels were determined in 94 HD patients before and after a regular 4-h HD. We followed changes in these peptides during HD depending on age, sex, HF (NYHA classification and left ventricular ejection fraction [LVEF]), duration on HD, presence of hypertension, coronary artery disease, type of membrane used for HD [low-flux (LFx) or high-flux (HFx)] and body mass change during HD. Furthermore, patients' basic medication and creatinine levels and presence of diabetes mellitus were monitored. Results: Respectively, 94% and 100% of the patients had pre-dialysis concentrations of BNP and NT-proBNP above the cut-off values for HF. The marker levels correlated significantly both before and after HD (r = 0.903 and 0.888, respectively, p < 0.001). BNP levels significantly decreased ( p < 0.0001), whereas NT-proBNP signifi cantly increased ( p < 0.0001) during HD on LFx membranes. HD on HFx membranes caused greater decrease of BNP (compared to LFx membranes, p < 0.001), but also a decrease of NT-proBNP ( p < 0.001). We did not find any significant differences in marker levels for HF and non-HF patients (NYHA classification). However, both peptides reached higher levels in the group with LVEF <= 50% ( p < 0.001 for both peptides). Body mass change during HD negatively correlated only with the change of NT-proBNP (r = - 0.27, p < 0.05). In the multiple regression model, the change of both peptides during HD was significantly influenced by membrane type (p = 0.003 for BNP and p = 0.001 for NT-proBNP). NT-proBNP change during HD was further significantly influenced by LVEF (p = 0.012), sex (p = 0.002) and duration on HD (p = 0.006). Conclusions: Both BNP and NT-proBNP levels were signifi cantly increased in HD patients prior to dialysis. The change in concentrations of both peptides during HD is influenced by membrane type. HD probably triggers increased production of both peptides and this increase is emphasized by impaired LVEF. This fact can be clinically observed only on NT-proBNP levels, because BNP levels are biased by significant removal of this protein during HD. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:C162 / C172
页数:11
相关论文
共 37 条
[1]  
AKIBA T, 1995, CLIN NEPHROL, V44, pS61
[2]   PLASMA-CONCENTRATIONS AND COMPARISONS OF BRAIN NATRIURETIC PEPTIDE AND ATRIAL-NATRIURETIC-PEPTIDE IN NORMAL SUBJECTS, CARDIAC TRANSPLANT RECIPIENTS AND PATIENTS WITH DIALYSIS-INDEPENDENT OR DIALYSIS-DEPENDENT CHRONIC-RENAL-FAILURE [J].
BUCKLEY, MG ;
SETHI, D ;
MARKANDU, ND ;
SAGNELLA, GA ;
SINGER, DRJ ;
MACGREGOR, GA .
CLINICAL SCIENCE, 1992, 83 (04) :437-444
[3]   Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling [J].
Cataliotti, A ;
Malatino, LS ;
Jougasaki, M ;
Zoccali, C ;
Castellino, P ;
Giacone, G ;
Bellanuova, I ;
Tripepi, R ;
Seminara, G ;
Parlongo, S ;
Stancanelli, B ;
Bonanno, G ;
Fatuzzo, P ;
Rapisarda, F ;
Belluardo, P ;
Signorelli, SS ;
Heublein, DM ;
Lainchbury, JG ;
Leskinen, HK ;
Bailey, KR ;
Redfield, MM ;
Burnett, JC .
MAYO CLINIC PROCEEDINGS, 2001, 76 (11) :1111-1119
[4]   Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans [J].
Clerico, A ;
Iervasi, G ;
Mariani, G .
HORMONE AND METABOLIC RESEARCH, 1999, 31 (09) :487-498
[5]  
Clerico A, 2000, CLIN CHEM, V46, P1529
[6]   Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review [J].
Clerico, A ;
Emdin, M .
CLINICAL CHEMISTRY, 2004, 50 (01) :33-50
[7]   Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis [J].
Clerico, A ;
Caprioli, R ;
Del Ry, S ;
Giannessi, D .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2001, 24 (01) :24-30
[8]   PLASMA NATRIURETIC PEPTIDES AND CARDIAC VOLUME DURING ACUTE CHANGES IN INTRAVASCULAR VOLUME IN HEMODIALYSIS-PATIENTS [J].
CORBOY, JC ;
WALKER, RJ ;
SIMMONDS, MB ;
WILKINS, GT ;
RICHARDS, AM ;
ESPINER, EA .
CLINICAL SCIENCE, 1994, 87 (06) :679-684
[9]   Association between brain natriuretic peptide and extracellular water in hemodialysis patients [J].
Fagugli, RM ;
Palumbo, B ;
Ricciardi, D ;
Pasini, P ;
Santirosi, P ;
Vecchi, L ;
Pasticci, F ;
Palumbo, R .
NEPHRON CLINICAL PRACTICE, 2003, 95 (02) :C60-C66
[10]   Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis [J].
Goto, T ;
Takase, H ;
Toriyama, T ;
Sugiura, T ;
Kurita, Y ;
Tsuru, N ;
Masuda, H ;
Hayashi, K ;
Ueda, R ;
Dohi, Y .
NEPHRON, 2002, 92 (03) :610-615